Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660368 · ClinicalTrials.gov registry record · Phase 2
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
A Phase 2 study of Relapsed or Refractory Acute Myeloid Leukemia (AML), sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT06660368 is a Phase 2 study of Relapsed or Refractory Acute Myeloid Leukemia (AML) that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 52 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06660368, a Phase 2 study of Relapsed or Refractory Acute Myeloid Leukemia (AML), is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660368
The ClinicalTrials.gov registry entry for NCT06660368 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT06660368 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06660368 about?
NCT06660368 is a clinical study titled "BCL2i CLAG-M in R/R Acute Myeloid Leukemia". This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the ad...
What is the current status of trial NCT06660368?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2024-11-26. Estimated completion is 2027-11.
What conditions does trial NCT06660368 study?
This clinical trial studies the following conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT06660368?
The interventions under investigation include: Venetoclax (DRUG), Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen (DRUG).
Who is sponsoring clinical trial NCT06660368?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660368 being conducted?
This trial has 2 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.